A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

NCT01646177 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1346

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Placebo
DRUG: 50 mg etanercept
DRUG: 80 mg ixekizumab

Sponsor

Eli Lilly and Company